NVGN Novogen announces milestone with its super-benzopyran (:SBP) drug program; extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers (NVGN) : NVGN announced that it has achieved a key milestone with its super-benzopyran (:SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.